Detalhe da pesquisa
1.
Support to early clinical decisions in drug development and personalised medicine with checkpoint inhibitors using dynamic biomarker-overall survival models.
Br J Cancer
; 129(9): 1383-1388, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36765177
2.
Model-based approach for methoxy polyethylene glycol-epoetin beta drug development in paediatric patients with anaemia of chronic kidney disease.
Br J Clin Pharmacol
; 86(4): 801-811, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31770451
3.
Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma.
Pharm Res
; 37(12): 252, 2020 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33258982
4.
A modeling and simulation-based assessment of the impact of confounding factors on the readout of a sildenafil survival trial in pulmonary arterial hypertension.
J Pharmacokinet Pharmacodyn
; 46(5): 499-509, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31538282
5.
Tumor growth and overall survival modeling to support decision making in phase Ib/II trials: A comparison of the joint and two-stage approaches.
CPT Pharmacometrics Syst Pharmacol
; 2024 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38629452
6.
Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma.
Clin Transl Sci
; 17(6): e13825, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38808543
7.
Modeling Alzheimer's disease progression utilizing clinical trial and ADNI data to predict longitudinal trajectory of CDR-SB.
CPT Pharmacometrics Syst Pharmacol
; 12(7): 1029-1042, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37101394
8.
Clinical Pharmacology Applications of Real-World Data and Real-World Evidence in Drug Development and Approval-An Industry Perspective.
Clin Pharmacol Ther
; 114(4): 751-767, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37393555
9.
Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150.
Clin Cancer Res
; 29(6): 1047-1055, 2023 03 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36595566
10.
Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumors.
Front Pharmacol
; 13: 974423, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36225583
11.
Real-world data prognostic model of overall survival in patients with advanced NSCLC receiving anti-PD-1/PD-L1 immune checkpoint inhibitors as second-line monotherapy.
Cancer Rep (Hoboken)
; 5(10): e1578, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35075804
12.
Characterization of exposure-response relationships of ipatasertib in patients with metastatic castration-resistant prostate cancer in the IPATential150 study.
Cancer Chemother Pharmacol
; 90(6): 511-521, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36305957
13.
Population Pharmacokinetics of Ipatasertib and Its Metabolite in Cancer Patients.
J Clin Pharmacol
; 61(12): 1579-1591, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34273118
14.
Results of a Dose-Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Clin Pharmacol Drug Dev
; 10(10): 1142-1155, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33788415
15.
Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma.
Leuk Lymphoma
; 61(12): 2905-2914, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32705923
16.
Integrated Two-Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non-Hodgkin Lymphoma.
CPT Pharmacometrics Syst Pharmacol
; 9(1): 48-59, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31749251
17.
Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer.
J Immunother Cancer
; 7(1): 314, 2019 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31753029
18.
Population pharmacokinetics of oseltamivir when coadministered with probenecid.
J Clin Pharmacol
; 48(8): 935-47, 2008 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-18524996
19.
Correction: Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150.
Clin Cancer Res
; 29(20): 4314, 2023 Oct 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37828897
20.
Exposure-Response and Tumor Growth Inhibition Analyses of the Monovalent Anti-c-MET Antibody Onartuzumab (MetMAb) in the Second- and Third-Line Non-Small Cell Lung Cancer.
AAPS J
; 19(2): 527-533, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28028730